Papel de los fármacos inhibidores de mTOR en la prevención del cáncer cutáneo no melanoma en los pacientes receptores de un trasplante de órgano sólido

[1]  J. Zaltzman.  Is There a Role for mTOR Inhibitors in Renal Transplantation? , 2017, Transplantation.

[2]  M. Casey,et al.  Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States , 2017, Transplantation.

[3]  D. Sesok-Pizzini,et al.  A2/A2B to B Renal Transplantation: Past, Present, and Future Directions , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  S. Arron,et al.  Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs). , 2015, Journal of the American Academy of Dermatology.

[5]  G. Knoll,et al.  Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data , 2014, BMJ : British Medical Journal.

[6]  G. Russ,et al.  A Systematic Review of Conversion From Calcineurin Inhibitor to Mammalian Target of Rapamycin Inhibitors for Maintenance Immunosuppression in Kidney Transplant Recipients , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  Jean Kanitakis,et al.  Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients. , 2013, Anticancer research.

[8]  J. D. de Fijter,et al.  Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Decullier,et al.  Sirolimus and secondary skin-cancer prevention in kidney transplantation. , 2012, The New England journal of medicine.

[10]  G. Russ,et al.  Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  F. Schena,et al.  Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial , 2011, Transplantation.

[12]  D. Lott,et al.  Aggressive Behavior of Nonmelanotic Skin Cancers in Solid Organ Transplant Recipients , 2010, Transplantation.

[13]  R. Kaufmann,et al.  Switch to a Sirolimus‐Based Immunosuppression in Long‐Term Renal Transplant Recipients: Reduced Rate of (Pre‐)Malignancies and Nonmelanoma Skin Cancer in a Prospective, Randomized, Assessor‐Blinded, Controlled Clinical Trial , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  B. Kahan,et al.  Maintenance Immunosuppression with Target-of-Rapamycin Inhibitors is Associated with a Reduced Incidence of De Novo Malignancies , 2005, Transplantation.

[15]  M. Fernández-Figueras,et al.  A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients , 2003, The British journal of dermatology.

[16]  D. Berg,et al.  Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. , 2002, Journal of the American Academy of Dermatology.